Showing 2181-2190 of 5643 results for "".
- PulseSight Therapeutics Launches to Advance Non-Viral Gene Therapies for Severe Retinal Diseaseshttps://modernod.com/news/pulsesight-therapeutics-launches-to-advance-non-viral-gene-therapies-for-severe-retinal-diseases/2482134/PulseSight Therapeutics launched today with a portfolio that includes two first-in-class late-stage preclinical drugs for wet and dry age-related macular diseases (AMD), including geographic atrophy (GA). PulseSight’s proprietary non-viral gene therapy ocu
- Nordic Group Appoints Eric Donnenfeld, MD, as Medical Advisory Board Chairhttps://modernod.com/news/nordic-group-appoints-eric-donnenfeld-md-as-medical-advisory-board-chair/2482132/Amring Pharmaceuticals, a subsidiary of Nordic Group, announced that ophthalmologist Eric D. Donnenfeld, MD, will chair its US Medical Advisory Board, which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, O
- Optos Celebrates Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achievedhttps://modernod.com/news/optos-celebrates-milestones-25000-devices-installed-globally-and-extensive-clinical-publications-achieved/2482131/Optos announced a dual milestone achievement of over 25,000 devices installed worldwide, and the collection of 2,500 clinical and peer-reviewed studies spanning 235 disease states, acccording to a company news release. "This remarkable double milestone reflects the unwavering
- SightGlass Vision Receives FDA Breakthrough Device Designation for Myopia Spectacle Lenshttps://modernod.com/news/sightglass-vision-receives-fda-breakthrough-device-designation/2482118/The FDA has granted Breakthrough Device designation to SightGlass Vision's Diffusion Optics Technology (DOT) spectacle lenses, which are intended to slow myopia progression in children. The design is the first to use the contrast management mechanism of action, incorporating thousan
- WashU Awarded up to $20M to Create Portable Device to Scan for Eye Diseaseshttps://modernod.com/news/washu-awarded-up-to-20m-to-create-portable-device-to-scan-for-eye-diseases/2482115/Chao Zhou, a professor of biomedical engineering in the McKelvey School of Engineering at Washington University in St. Louis, has been working to improve optical coherence tomography (OCT) systems that can conduct high-resolution imaging of the eyes. Now, with an up to $20 million contract from t
- FDA Gives Green Light to Okyo Pharma for Clinical Trial Design for OK-101 in Neuropathic Corneal Painhttps://modernod.com/news/fda-gives-green-light-to-okyo-pharma-for-clinical-trial-design-for-ok-101-in-neuropathic-corneal-pain/2482109/Okyo Pharma announced that the FDA has cleared OK-101 as its first investigational new drug (IND) application for the treatment of Neuropathic Corneal Pain (NCP). The initial IND submission to FDA proposed an open-label design for the clinical trial. Based on positiv
- New Spiral-Shaped Lens Designed to Improve Vision at Range of Distances and Lighting Conditionshttps://modernod.com/news/new-spiral-shaped-lens-designed-to-improve-vision-at-a-range-of-distances/2482108/French researchers have developed a spiral-shaped lens that is designed to maintain clear focus at different distances in varying light conditions. Published in the journal Optica,1 the researchers say the lens works much like progressive lenses used f
- Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japanhttps://modernod.com/news/nicox-and-kowa-enter-into-agreement-for-ncx-470-development-and-commercialization-in-japan/2482106/Nicox SA announced the signature of an agreement granting Kowa exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension. Under the
- American Vision Partners Notifies Patients of Cybersecurity Incidenthttps://modernod.com/news/american-vision-partners-notifies-patients-of-cybersecurity-incident/2482103/Medical Management Resource Group (MMRG), doing business as American Vision Partners, provided notice of a cybersecurity incident affecting information the company maintains in connection with performing services. American Vision Partners provides administrative services to ophthalmolog
- Théa Acquires Rights to KIO-301 for the Treatment of Inherited Retinal Diseases in $301 Million Dealhttps://modernod.com/news/thea-acquires-rights-to-kio-301-for-the-treatment-of-inherited-retinal-diseases-in-301-million-deal/2482089/Kiora Pharmaceuticals announced that it has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), a sister company of Laboratoires Théa under with Kiora granted Théa exclusive worldwide development and commercialization rig